Cowen & Co. analyst Ritu Baral maintained a Buy rating on NGM Biopharmaceuticals Inc (NGM) today and set a price target of $25. The company’s shares closed on Friday at $13.30.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 26.7% and a 51.4% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, ACADIA Pharmaceuticals Inc, and Allena Pharmaceuticals Inc.
NGM Biopharmaceuticals Inc has an analyst consensus of Strong Buy, with a price target consensus of $25.33.
See today’s analyst top recommended stocks >>
The company has a one-year high of $18.75 and a one-year low of $12. Currently, NGM Biopharmaceuticals Inc has an average volume of 173.4K.
Based on the recent corporate insider activity of 16 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of NGM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
NGM Biopharmaceuticals, Inc. engages in the discovery and development of therapeutics for major diseases with an initial focus on cardio-metabolic and liver diseases. Its portfolio if composed of product candidates which focuses on non-alcoholic steatohepatitis, type 2 diabetes, obesity, oncology and age-related macular degeneration.
